Advertisement
U.S. markets close in 15 minutes
  • S&P 500

    5,259.73
    +11.24 (+0.21%)
     
  • Dow 30

    39,831.42
    +71.34 (+0.18%)
     
  • Nasdaq

    16,393.88
    -5.64 (-0.03%)
     
  • Russell 2000

    2,122.77
    +8.42 (+0.40%)
     
  • Crude Oil

    83.07
    +1.72 (+2.11%)
     
  • Gold

    2,239.90
    +27.20 (+1.23%)
     
  • Silver

    24.96
    +0.21 (+0.84%)
     
  • EUR/USD

    1.0791
    -0.0039 (-0.36%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • dólar/libra

    1.2622
    -0.0016 (-0.13%)
     
  • USD/JPY

    151.4020
    +0.1560 (+0.10%)
     
  • Bitcoin USD

    70,872.94
    +2,376.66 (+3.47%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Spin-Off Expert Eyes 3 Ways to Win With Recro Pharma

Investing in stock spin-offs is a great way to generate alpha. The Bloomberg spin-off index has generated annual returns of 13.99% since inception in 2002, beating the S&P 500 by 4.22% per year, observes Rich Howe, editor of the specialized advisory service, Spin-Off Stock Investing.

What is less well known is that investing in the parent of the spin-off can also be a profitable strategy. Recro Pharma (REPH), an outsourced manufacturer of pharmaceutical drugs, is a perfect example of why.

More from Rich Howe: Top Picks 2020: KLX Energy Services

In November 2019, Recro Pharma Inc. spun off its money losing Acute Care Drug business, in a taxable transaction. This Acute Care Drug business was expensive to operate and masked the strong fundamentals of REPH’s remaining business — an outsource manufacturing and development organization (CDMO).

Recro Pharma’s remaining business is defensive, on pace to grow revenue 34% in 2019, and generates a 39% EBITDA margin. Despite robust fundamentals, REPH trades at 8.9x 2020 EBITDA and 15.3x 2020 EPS, a massive discount to peers.

The secular trend of pharmaceutical companies outsourcing manufacturing in ordre to cut costs is driving continued growth for CDMO companies. The industry is fragmented and M&A activity has been very strong.

See also: Take these Values to the Bank: JPMorgan, BofA, Citi and Goldman Sachs

With Recro Pharma, we have three ways to win.

First, REPH is a defensive, high margin business that will grow earnings 15% to 20% in 2020. Thus, even without multiple expansion, the stock should generate a 15% to 20% return.

Second, earnings estimates (both EBITDA and EPS) are way too low for 2020. Consensus EPS is $0.58, but I believe the company will earn $1.13. If REPH beats EPS estimates, the Street will have no choice but to re-rate the stock higher.

Third, REPH is an excellent acquisition candidate. 5 out of 7 peers that REPH lists in its 10-k have recently been acquired. The median acquisition EV/EBITDA multiple of 16.5x is significantly above REPH’s current valuation of 8.9x. In an acquisition scenario, there could be 50% to 100% upside. Buy Recro Pharma to take advantage of significant upside optionality.

Advertisement